British Columbia First Province to Cover Dexcom G6 Continuous Glucose Monitoring System for People With Type 1 and Type 2 Diabetes on Intensive Insulin Therapy

Short article material

  • Dexcom CGM usage is shown to enhance glycemic control1,2and can minimize the threat of expensive long-term diabetes-related issues compared to fingerstick tracking.3

BURNABY, British Columbia — Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time constant glucose tracking (CGM), revealed today that individuals with diabetes who are on extensive insulin treatment, age 2 years or older, might now be qualified for provincial protection of the Dexcom G6 CGM System through BC PharmaCare. This protection growth remains in line with Dexcom’s objective to make it much easier for individuals living with diabetes to experience the advantages of utilizing a CGM system for their diabetes management.

“Improved access to CGM technology elevates diabetes management for everyone in a patient’s circle of care. As an endocrinologist and medical director at a clinic specifically dedicated to diabetes care, I am appreciative that today’s announcement will benefit so many people in the province,” stated Dr. Tom Elliott, Medical Director of B.C. Diabetes. CGM results in much better glycemic control for clients1,2 and offers doctors much better insight into clients’ glucose levels to make treatment choices. CGM usage might result in less journeys to the emergency clinic by assisting users prevent serious hypoglycemic episodes.4


Short article material

British Columbia signs up with Yukon, Quebec and Saskatchewan to provide public protection of CGM systems under provincial health insurance. In addition,Prince Edward Island and Manitoba have likewise just recently revealed prepare for financing based upon their 2021 spending plan platforms. For protection in B.C., clients need to fulfill the protection requirements, be registered in qualified PharmaCare strategies, and fulfill any deductible requirements. Today’s statement marks a substantial achievement in increasing access to life altering innovation utilized in the management of diabetes and acknowledges the effect CGM innovation can have on those who need extensive insulin treatment to handle their type 2 diabetes in addition to those living with type 1 diabetes.

“As a BC-based company, we are thrilled by today’s announcement and the province’s commitment to the diabetes community,” states Laura Endres, Vice President and General Supervisor of Dexcom Canada. “We have seen the impact of improved access to CGM to truly change lives, and we look forward to continuing our work toward access for all those impacted by diabetes across Canada.”

The Dexcom G6 CGM System consists of a little, wearable sensing unit that determines glucose simply listed below the skin; a transmitter to continually and wirelessly send out glucose levels to a display screen gadget; and a suitable clever gadget* or receiver that shows real-time glucose information to users without the requirement for fingersticks or scanning. And with real-time notifies, consisting of a predictive Urgent Low Quickly alert, the Dexcom G6 can alert the user in advance of hypoglycemia — permitting time to take suitable action prior to it occurs — day or night. As part of the BC PharmaCare protection program, users will now have the ability to get their Dexcom CGM provides through a taking part regional drug store.

To find out more about the protection requirements for BC PharmaCare, please check out and BC PharmaCare’s site area associated to Diabetes Products.

About Dexcom, Inc.

Dexcom, Inc. empowers individuals to take control of diabetes through ingenious constant glucose tracking (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has actually become a leader of diabetes care innovation. By listening to the requirements of users, caretakers, and companies, Dexcom streamlines and enhances diabetes management all over the world. To find out more about Dexcom CGM, check out


Short article material

If your glucose notifies and readings from the G6 do not match signs or expectations, utilize a blood sugar meter to make diabetes treatment choices.

* For a list of suitable gadgets, please check out

Dr. Tom Elliott was not made up for any media work. He has actually been a paid speaker for Dexcom Canada, Co.


1 Beck RW, Riddlesworth T, Ruedy K, et al. Result of constant glucose tracking on glycemic control in grownups with type 1 diabetes utilizing insulin injections: The DIAMOND randomized scientific trial. JAMA 2017;317(4):371-8.

2 Welsh JB, Gao P, Derdzinski M, et al. Precision, Usage, and Efficiency Comparisons of Various Constant Glucose Tracking Systems. Diabetes Technol Ther 2019;21(3):128-32.

3 Roze S, Isitt J, Smith-Palmer J, Lynch P. Examination of the Long-Term Cost-Effectiveness of the Dexcom G6 Constant Glucose Display Versus Self Tracking of Blood Sugar in Individuals with Type 1 Diabetes in Canada. Poster discussion provided at: 2020 Canadian Association for Population Therapies; October 27, 2020.

4 Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic Results with Early Initiation of Constant Glucose Tracking System in Just Recently Identified Clients with Type 1 Diabetes. Diabetes Technol Ther 2019;21(1):6-10.

View source variation on



Alena Atkinson, 705.206.9991
Veritas Communications




Postmedia is devoted to keeping a vibrant however civil online forum for conversation and motivate all readers to share their views on our posts. Remarks might use up to an hour for small amounts prior to appearing on the website. We ask you to keep your remarks appropriate and considerate. We have actually allowed e-mail notices—you will now get an e-mail if you get a reply to your remark, there is an upgrade to a remark thread you follow or if a user you follow remarks. Visit our Neighborhood Standards to learn more and information on how to change your e-mail settings.

Jobber Wiki author Frank Long contributed to this report.